These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 24768047)

  • 1. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
    Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
    Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binary-copolymer system base on low-density lipoprotein-coupled N-succinyl chitosan lipoic acid micelles for co-delivery MDR1 siRNA and paclitaxel, enhances antitumor effects via reducing drug.
    Yang SD; Zhu WJ; Zhu QL; Chen WL; Ren ZX; Li F; Yuan ZQ; Li JZ; Liu Y; Zhou XF; Liu C; Zhang XN
    J Biomed Mater Res B Appl Biomater; 2017 Jul; 105(5):1114-1125. PubMed ID: 27008163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
    Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
    Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabrication of self-assembled chitosan-dispersed LDL nanoparticles for drug delivery with a one-step green method.
    Tian J; Xu S; Deng H; Song X; Li X; Chen J; Cao F; Li B
    Int J Pharm; 2017 Jan; 517(1-2):25-34. PubMed ID: 27845214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
    Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
    Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
    Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles.
    Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X
    Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.
    Guo Y; Chu M; Tan S; Zhao S; Liu H; Otieno BO; Yang X; Xu C; Zhang Z
    Mol Pharm; 2014 Jan; 11(1):59-70. PubMed ID: 24229050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
    Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
    Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
    Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
    J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
    Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.
    Chang JE; Shim WS; Yang SG; Kwak EY; Chong S; Kim DD; Chung SJ; Shim CK
    Pharm Res; 2012 Mar; 29(3):795-805. PubMed ID: 21971829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
    Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
    Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
    Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
    Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
    Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
    Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
    Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
    J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway.
    Ye BL; Zheng R; Ruan XJ; Zheng ZH; Cai HJ
    Biochem Biophys Res Commun; 2018 Jan; 495(1):414-420. PubMed ID: 29097204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.